Benet Nomdedeu

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

Journal: Leukemia

Published: May 15, 2020

Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML.

Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML.

Journal: Scientific reports

Published: April 03, 2018

Excess mortality in the myelodysplastic syndromes.

Excess mortality in the myelodysplastic syndromes.

Journal: American journal of hematology

Published: November 01, 2016

Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.

Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 07, 2016

Further psychometric validation of the GAH scale: Responsiveness and effect size.

Further psychometric validation of the GAH scale: Responsiveness and effect size.

Journal: Journal of geriatric oncology

Published: June 01, 2016

Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.

Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: April 06, 2016

Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes.

Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes.

Journal: Genes, chromosomes & cancer

Published: July 27, 2015

Paraspinal extramedullary hematopoiesis in hereditary spherocytosis with a concurrent follicular lymphoma: case report and review of the literature.

Paraspinal extramedullary hematopoiesis in hereditary spherocytosis with a concurrent follicular lymphoma: case report and review of the literature.

Journal: Diagnostic pathology

Published: June 19, 2015

Refining the Breakpoints of Three New Translocations Identified in Myelodysplastic Syndromes.

Refining the Breakpoints of Three New Translocations Identified in Myelodysplastic Syndromes.

Journal: Acta haematologica

Published: June 02, 2015

Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.

Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.

Journal: Leukemia

Published: March 03, 2015

Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML.

Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML.

Journal: Leukemia research

Published: March 01, 2015

Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.

Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.

Journal: The Lancet. Haematology

Published: February 01, 2015

Showing 1-12 of 23

Last Updated: 09/26/2026